Psoriasis: the choice of optimal topical corticosteroid drug
Journal Title: Український журнал дерматології, венерології, косметології - Year 2019, Vol 0, Issue 1
Abstract
Psoriasis is an immune-mediated skin disease that occupies one of the leading positions in the morbidity structure of the population of Ukraine. The main mechanism of triggering immunopathological processes in the skin is altered activity of CD4+, CD8+ T-lymphocytes, the synthesis of a number of pro-inflammatory cytokines (tumor necrosis factor a, interleukins-6, -8, -17, etc.) and growth factors (transforming growth factor a, vascular endothelial growth factor and others). The problem of treating psoriasis does not lose its relevance, despite the emergence of new methods of therapy and requires a personalized approach. The Ukrainian protocol for the management of patients with psoriasis (2015) determines topical glucocorticosteroids as first-choice therapy for mild or moderate psoriatic skin lesions and only in the absence of a clinical effect from monotherapy with external agents or their combinations the possibility of other types of treatment is considered. Сorticosteroids, which have a powerful effect on various parts of the pathogenesis of dermatosis, represent a unique opportunity to directly affect the lesions and, accordingly, suppress the inflammatory process in the skin, significantly reduce or eliminate subjective symptoms without resorting to systemic treatment. The effectiveness of modern topical steroids in the treatment of plaque psoriasis has level I evidence (recommendations of level A). The drug of choice in treating patients with psoriasis is the original synthetic steroid mometasone furoate 0.1 % (ointment, cream and lotion Elocom). The drug is characterized by the ability to quickly and durably block the synthesis of proinflammatory cytokines and reduce the severity of inflammation. Its predominantly extragenomic mechanism of action, high lipophilicity and minimal systemic absorption reduce the risk of side effects. Topical steroid mometasone furoate 0.1 % provides quick clinical effect, ease of use due to universal dosage forms, and safety when used correctly.
Authors and Affiliations
L. A. Bolotna
Keywords
Related Articles
- EP ID EP577241
- DOI 10.30978/UJDVK2019-1-55
- Views 127
- Downloads 0
Atopic dermatitis and eczema: emergency care and effective treatment
Objective — to study the effectiveness and safety of the use of combined topical agents with a triple mechanism of action (antiinflammatory, antibacterial and antimycotic) in the treatment of patients with eczema and at...
Cosmetic defects, provoked by scars that cause patients displeasure and force them seek the medical care
Objective — to clarify what cosmetic defects, provoked by the scaring, discomfort patients and force them ask for the medical care. Materials and methods. Sixty patients, aged from 12 to 67 years (42 females and 18 mal...
Chronic atrophic acrodermatitis: сlinical сases
Two cases of rare dermatosis — chronic atrophic acrodermatitis are described. Etiology of disease, clinical manifestations, differential diagnosis are presented.
Role of chronic stress, state and trait anxiety and certain neuroendocrine, metabolic and immunological disorders in the pathogenesis of acne
Objective — to study a pathogenic role of chronic stress, state and trait anxiety, certain metabolic neuroendocrine and immunological disorders in the development of acne in women, depending on the duration of the diseas...
Verrucous psoriasis: clinical case
Case of rare clinical form of psoriasis — verrucous psoriasis — is described. Diagnostic mistakes and results of differential diagnostics are presented.